ALPHA-GLUCOSIDASE INHIBITORS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

ALPHA-GLUCOSIDASE INHIBITORS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The Alpha-glucosidase Inhibitors Market is set to witness a CAGR of more than 2% during the forecast period 2022-2027. The market is estimated to reach a value of about USD 5.1 billion by 2027.

The COVID-19 pandemic positively impacted the Alpha-glucosidase Inhibitors market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.

Alpha-glucosidase inhibitors are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates. Carbohydrates are converted into monosaccharides by alpha-glucosidase enzymes present in cells lining the intestine, enabling monosaccharides to be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of dietary carbohydrates on blood sugar. Alpha-glucosidase inhibitors are used to establish greater glycemic control over hyperglycemia in diabetes mellitus type 2, they may be used as monotherapy in conjunction with an appropriate diabetic diet and exercise, or they may be used in conjunction with other anti-diabetic drugs. Therefore, they have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.

In May 2021, the World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to medicines and health products for the treatment of diabetes and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsRising diabetes prevalence globally

The diabetes population globally is expected to rise by 1.5% during the forecast period.

Currently, about 10% of all diabetes cases are Type-1, and the remaining are Type-2. As per International Diabetes Federation (IDF), the adult diabetes population in 2021 is approximately 537 million, and this number is going to increase by 643 million in 2030. The rate of newly diagnosed cases of Type 1 and Type 2 diabetes is seen to increase, mainly due to obesity, unhealthy diet, and sedentary lifestyle. The increased prevalence of diabetic patients and healthcare expenditure worldwide are indications of the increased inclination to diabetic drugs.

Type 2 diabetes (T2D) is increasingly prevalent and associated with an increased risk for cardiovascular and renal disease. Along with lifestyle changes, Alpha-glucosidase inhibitors are used in the treatment of type 2 diabetes mellitus, alone or combined with other antidiabetic drugs. They may also be used in patients with impaired glucose tolerance and delay the occurrence of type 2 diabetes mellitus in these patients. They are particularly useful for patients who are at risk of hypoglycemia or lactic acidosis, and thus, are not suitable candidates for other antidiabetic drugs such as sulfonylureas and metformin. The FDA approved AGIs for the treatment of type 2 diabetes mellitus.

In April 2021 WHO launched the Global Diabetes Compact, a global initiative aiming for sustained improvements in diabetes prevention and care, with a particular focus on supporting low and middle-income countries. The Compact is bringing together national governments, UN organizations, nongovernmental organizations, private sector entities, academic institutions, philanthropic foundations, people living with diabetes, and international donors to work on a shared vision of reducing the risk of diabetes and ensuring that all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable, and quality treatment and care.

Therefore, due to increased prevalence and the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.

Middle East and Africa is expected to register the highest CAGR in Alpha-glucosidase Inhibitors Market

During the forecast period, the Middle East and Africa is expected witness a CAGR of more than 3.8%.

Alpha-glucosidase inhibitors are pills that treat type 2 diabetes. There are two medications in this group, or class, of drugs: acarbose (Precose) and miglitol (Glyset). They help keep the amount of glucose in the blood from going up too fast after meals. 73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which places them at increased risk of developing type 2 diabetes. Diabetes is responsible for 796,000 deaths in the IDF MENA Region in 2021. USD 33 billion was spent on healthcare for people with diabetes in 2021.

The Middle East and African region have witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels.

The Government has been working on plans and policies to control the outcomes of diabetes. For instance, Saudi Government, in July 2022, announced that Saudi Arabia has seen growing demand for quality healthcare services spurred by changes including an increasing and aging population, and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are both involved to work on healthcare entities, certifications, and regulations. The government is taking steps to have 100 percent of Saudi citizens covered by insurance and is working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.

Owing to the aforementioned factors the market is expected to grow during the forecast period.

Competitive Landscape

The market studied is highly fragmented into many manufacturers like Bayer, SunPharma, Pfizer, Takeda, and Zydus holding a presence in all regions. The Asia-Pacific contributes the highest market share in 2021, due to many generic products in the region, especially China and India.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.